Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha joining 51 (TRAJ51)
- Target
- TRAJ51
- Molecular classification
- Other (Pseudogene segment in T cell receptor alpha locus—does not encode a protein), T cell receptor gene segment (J segment specifically)
01
Overview
TRAJ51 is a joining (J) segment within the T cell receptor alpha locus on chromosome 14, classified as a pseudogene in humans. The T cell receptor itself, expressed on T lymphocytes, is integral to antigen recognition and immune response, but TRAJ51 does not produce a functional protein and is incapable of direct receptor activity. T cell receptor diversity is generated by recombination of variable (V), joining (J), and constant (C) gene segments, but segments annotated as pseudogenes—such as TRAJ51—do not participate in forming functional receptors
- Other names
- T cell receptor alpha joining 51TRAJ51TRAV/DV (segment related in recombination context)
02
Mechanism of action
Not applicable; no drugs target TRAJ51 specifically.
03
Biological functions
Genomic component of T cell receptor alpha locusParticipates in generation of T cell receptor diversity through V(D)J recombination (in species where functional; this segment is a pseudogene in humans)
04
Disease associations
None specific to TRAJ51 as a pseudogene; the T cell receptor system overall has roles in autoimmunity, infection, and cancer, but TRAJ51 itself is not implicated as a functional disease gene
05
Safety considerations
None specific; pseudogenes are generally not associated with safety concerns in therapeutics.
06
Interacting drugs
None known. Pseudogene segments do not interact with drugs directly.
07
Biomarkers
None known for patient selection or efficacy monitoring.
Beyond the preview
Go deeper on T cell receptor alpha joining 51 (TRAJ51).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T cell receptor alpha joining 51 (TRAJ51).